Cumberland, Astellas sales and marketing update

Cumberland acquired from Astellas U.S. rights to commercialize Vaprisol, a dual vasopressin 1a (V1a) receptor and V2 receptor antagonist marketed to treat hyponatremia in the critical care setting. ...